Abstract
Ifosfamide/mesna was given to 97 patients who had malignant solid tumors diagnosed before they were 21 years of age. Patients received 1.6 g/m2 ifosfamide daily x 5, given i.v. over 15 min, followed by 400 mg/m2 i.v. mesna at 15 min and 4 and 6 h after ifosfamide. Responses were noted in patients with osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma and other soft-tissue sarcomas, rhabdoid tumor, neuroblastoma, Wilms' tumor, primitive neuroectodermal tumor, retinoblastoma, germ-cell tumors, and B-cell lymphoma. Toxicity included mild to moderate nausea and vomiting, transient, reversible myelosuppression, transient elevations of serum blood urea nitrogen (BUN) and creatinine and liver enzymes, infections, and self-limiting neurotoxicity characterized by changes in mental status, motor dysfunction, cranial nerve palsy, cerebellar dysfunction, and seizures. Neurotoxic symptoms were generally seen in patients who had previously received cisplatin. Ifosfamide is an important alkylating agent that should be combined with other agents in phase II and III trials. Alternate dose schedules should also be investigated.
Citations
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·S P LowisA W Craft
Jan 1, 1995·Journal of Neuro-oncology·R L HeidemanR Kadota
Jan 20, 1990·Lancet·T CernyM Lind
Mar 10, 2004·The Journal of Laboratory and Clinical Medicine·Katarina AleksaGideon Koren
Dec 9, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J S Whelan
Jun 1, 2012·Pediatric Blood & Cancer·Angela D Trobaugh-Lotrario, James H Feusner
Apr 21, 2010·Pediatric Blood & Cancer·Roderick SkinnerAndrew D J Pearson
Apr 1, 1994·Cancer Treatment Reviews·M K Tuxen, S W Hansen
Jan 27, 2011·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Yng-Tay ChenJiunn-Wang Liao
May 9, 2007·DNA Repair·Ryan J HansenM Eileen Dolan
Jun 15, 2010·Biochemical Pharmacology·Fei LiJeffrey R Idle
Aug 10, 2007·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Premila AbrahamEmila Sugumar
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael S IsakoffRichard Gorlick
Dec 18, 2001·Medical and Pediatric Oncology·E SandlerW Crist
May 19, 2000·British Journal of Cancer·R SkinnerM C Stevens
Mar 15, 1993·Cancer·A S PappoD N Shapiro
Dec 15, 1995·Cancer·P T HoF M Balis
Jun 1, 1993·Cancer·N M MarinaW H Meyer
Oct 26, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano FerrariUNKNOWN Italian and Scandinavian Sarcoma Groups
Jul 29, 2015·Biomedit︠s︡inskai︠a︡ khimii︠a︡·S A CherepanovV P Chekhonin
Feb 24, 2001·Journal of Pediatric Hematology/oncology·M S CairoG H Reaman
Jan 26, 2011·Journal of Clinical Pharmacology·Lauren N HanlyGideon Koren
Jan 1, 1994·Medical and Pediatric Oncology·B de CamargoM P Cusato
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S PappoH E Grier
Jul 29, 2005·Canadian Journal of Physiology and Pharmacology·Katarina AleksaGideon Koren
Apr 16, 2019·Pediatric Hematology and Oncology·Jassada BuaboonnamKleebsabai Sanpakit
Jan 1, 1992·Medical and Pediatric Oncology·A CangirP Salmonsen
Jun 1, 2021·Expert Opinion on Pharmacotherapy·Cristina Meazza, Sebastian Dorin Asaftei
Oct 27, 2004·Pediatric Blood & Cancer·Patrick Van WinkleMitchell S Cairo